Diabetic Nephropathy: Symptoms, Stages & Treatment

Diabetic Nephropathy: Symptoms, Stages, and Treatment Options

Diabetic nephropathy — also called diabetic kidney disease — is the single most common cause of end-stage renal disease (ESRD) in the world, and it is entirely preventable in most patients when caught early. If you or a loved one has diabetes and you have noticed foamy urine, swollen ankles, or unusual fatigue, these may be the first visible signs that high blood glucose has begun to damage your kidneys. As a transplant and hepatobiliary surgeon who has cared for more than 2,000 kidney patients over two decades in Mexicali, Baja California, I see firsthand how early education changes outcomes — and how late referrals rob patients of years of quality life. This guide explains what diabetic nephropathy is, how it progresses through five distinct clinical stages, which treatments slow or halt progression, and when kidney transplantation becomes the right path forward.

What Is Diabetic Nephropathy?

Diabetic nephropathy is progressive kidney damage caused by chronically elevated blood glucose levels. The kidneys filter approximately 200 liters of blood every day through millions of tiny filtering units called glomeruli. Sustained hyperglycemia thickens and scars the walls of these glomeruli — a process called glomerulosclerosis — reducing their ability to separate waste from nutrients. Over years, the kidneys lose more and more functional mass until they can no longer sustain life without dialysis or transplantation.

How Common Is It?

Diabetic nephropathy is responsible for approximately 40% of all new cases of ESRD globally. In Mexico, the situation is particularly acute: roughly 50% of patients currently receiving renal replacement therapy (dialysis) developed kidney failure because of diabetes. Given that Mexico has one of the highest rates of type 2 diabetes in the world — affecting more than 12 million adults — the burden on the healthcare system and on families is immense. For patients living along the US–Mexico border in California, Arizona, and Baja California, understanding this disease is both a personal and a community health imperative.

Why Does Diabetes Damage the Kidneys?

There are three main mechanisms through which sustained hyperglycemia injures the kidney:

1. Hemodynamic injury: High glucose causes the blood vessels entering the glomerulus (afferent arterioles) to dilate, increasing filtration pressure and accelerating glomerular wear.
2. Inflammatory and fibrotic signaling: Advanced glycation end-products (AGEs) activate cytokines like TGF-β, triggering fibrosis and scarring of the glomerular basement membrane.
3. Oxidative stress: Excess glucose generates reactive oxygen species (ROS) that damage the endothelial lining of glomerular capillaries.

All three mechanisms are amplified by coexisting hypertension — which is present in more than 70% of patients with type 2 diabetes — making blood pressure control just as critical as glucose control.

The 5 Stages of Diabetic Nephropathy

Diabetic nephropathy progresses through five stages, originally described by Danish physician Carl Erik Mogensen in the 1980s and still used clinically today. The key measurements are the estimated glomerular filtration rate (eGFR) and the urine albumin-to-creatinine ratio (UACR).

Stage 1 — Hyperfiltration (eGFR > 90 mL/min/1.73m²)

In the earliest stage, the kidneys actually work harder than normal. The glomeruli overfilter in response to rising glucose, and the eGFR may be elevated above 120 mL/min. The kidneys appear structurally enlarged on ultrasound. There are no symptoms whatsoever, and standard urine dipstick tests are normal. This stage is reversible: aggressive glucose control can normalize filtration pressure and prevent progression. Most patients in Stage 1 are unaware they have any kidney involvement.

Stage 2 — Silent Kidney Damage (eGFR 60–89 mL/min/1.73m²)

The glomerular basement membrane begins to thicken, and mesangial cells expand within the glomerulus. A sensitive urine test — the UACR — reveals microalbuminuria, defined as 30 to 300 mg of albumin per gram of creatinine in a spot urine sample. The word "microalbuminuria" is somewhat misleading because it does not mean there is a small amount of albumin; it means the albumin is too small in quantity to be detected by standard dipstick but large enough to signal injury when measured properly. Patients still feel completely well. This stage can last 10–15 years. Annual UACR screening in all diabetic patients exists precisely to catch disease here, before symptoms begin.

Stage 3 — Incipient Nephropathy (eGFR 30–59 mL/min/1.73m²)

The UACR crosses into macroalbuminuria territory (> 300 mg/g), and blood pressure rises even in patients who were previously normotensive. The eGFR begins a steady, measurable decline — often 10–14 mL/min per year without treatment intervention. Some patients notice foamy or bubbly urine for the first time. This foam is caused by excess albumin surfactant in the urine. Mild ankle swelling and fatigue may begin. Stage 3 is the last point at which aggressive multidrug intervention can meaningfully slow progression toward end-stage disease.

Stage 4 — Clinical (Overt) Nephropathy (eGFR 15–29 mL/min/1.73m²)

By this stage, protein loss through the urine is severe, and the patient may develop full nephrotic syndrome: massive edema of the legs and face, very low serum albumin, and in some cases ascites (fluid in the abdomen). Anemia becomes symptomatic because the damaged kidneys produce insufficient erythropoietin. Patients experience increasing fatigue, shortness of breath, and difficulty concentrating. Bone disease (renal osteodystrophy) begins as the kidneys lose their ability to activate vitamin D and excrete phosphorus. This is the stage at which most patients first arrive at a transplant surgery consultation.

Stage 5 — End-Stage Renal Disease (eGFR < 15 mL/min/1.73m²)

The kidneys can no longer sustain life without support. Patients experience uremia — the systemic toxic syndrome caused by waste product accumulation — characterized by nausea, vomiting, hiccups, confusion, pericarditis, and dangerous electrolyte disturbances including hyperkalemia. Renal replacement therapy — hemodialysis, peritoneal dialysis, or kidney transplantation — becomes essential. Kidney transplantation, when medically feasible, offers significantly better survival and quality of life than chronic dialysis. In my practice at Centro Médico González in Mexicali, patients are ideally referred for transplant evaluation when the eGFR falls to 20 mL/min — before reaching Stage 5 — so that pre-transplant workup can be completed without the emergency time pressure of uremic crisis.

Warning Symptoms: What Patients Notice and When

Because diabetic nephropathy is silent for years, most patients do not develop noticeable symptoms until Stage 3 or later. There are 8 warning signs that should prompt immediate kidney evaluation in any person with diabetes:

1. Foamy or frothy urine — a persistent, soapy foam that doesn't dissipate is caused by albumin in the urine (proteinuria). This is one of the earliest patient-reported symptoms and should never be dismissed as "just dehydration."
2. Swelling in the ankles, feet, or legs — fluid retention caused by falling serum albumin and impaired renal sodium excretion.
3. Puffiness around the eyes — especially noticeable in the morning, caused by protein loss.
4. Persistent fatigue — partly from anemia of chronic kidney disease, partly from the metabolic burden of uremia.
5. High blood pressure that is increasingly hard to control — as damaged kidneys retain sodium and activate the renin-angiotensin system.
6. Decreased urine output — in advanced stages the kidneys lose the ability to produce adequate urine volume.
7. Muscle cramps and weakness — caused by electrolyte imbalances (low calcium, high phosphorus).
8. Nausea, loss of appetite, or a metallic taste in the mouth — classic uremic symptoms in late-stage disease.

If you have diabetes and experience any combination of these symptoms, please seek a nephrology or transplant surgery evaluation without delay. In Mexicali, Dr. César Eduardo González Muñoz provides same-week consultations for patients arriving from Calexico, El Centro, Yuma, and across the Baja California region.

How Diabetic Nephropathy Is Diagnosed

Diagnosis requires three types of testing that should be performed annually in every patient with diabetes, starting at diagnosis for type 2 and after 5 years for type 1:

Urine Tests

• Urine Albumin-to-Creatinine Ratio (UACR): The cornerstone of early detection. A UACR between 30 and 300 mg/g indicates moderately increased albuminuria (formerly "microalbuminuria"). Above 300 mg/g indicates severely increased albuminuria (macroalbuminuria or clinical proteinuria). Two of three tests over a 3-month period should be abnormal before diagnosing diabetic nephropathy, to rule out transient elevations from exercise, fever, or urinary infection.
• 24-Hour Urine Protein: Used in advanced stages to quantify total protein loss.

Blood Tests

• Serum Creatinine and eGFR: The eGFR is calculated from serum creatinine using the CKD-EPI equation, accounting for age and sex. This single number summarizes overall kidney function.
• Serum BUN (Blood Urea Nitrogen): Rises as the kidneys lose the ability to excrete urea.
• HbA1c: Long-term glucose control, with a target of < 7% in most guidelines to slow nephropathy progression.
• Electrolytes, Bicarbonate, Hemoglobin: To assess for complications of CKD.

Imaging

Renal ultrasound assesses kidney size, echogenicity, and rules out obstruction. Kidneys damaged by diabetes typically appear small and echogenic (bright) in late stages, contrasting with the enlarged kidneys seen in Stage 1.

When Is Kidney Biopsy Needed?

A kidney biopsy is not routinely required for diabetic nephropathy when the clinical picture is classic. Biopsy is reserved for atypical presentations: rapid progression, absence of diabetic retinopathy, or when another concurrent glomerular disease is suspected.

Treatment: Slowing the Progression of Diabetic Kidney Disease

There are now more effective treatments for diabetic nephropathy than at any time in medical history. The current standard-of-care uses a multi-drug approach targeting glucose, blood pressure, inflammation, and fibrosis simultaneously.

1. Glycemic Control — The Foundation

Maintaining HbA1c below 7.0% (or 7.5% in elderly patients) remains the cornerstone of prevention and early treatment. Every 1% reduction in HbA1c is associated with a 37% reduction in microvascular complications, including nephropathy. In patients whose eGFR is already reduced, some older diabetes medications (notably metformin) require dose adjustment or discontinuation, making specialist-guided prescribing essential.

2. RAAS Blockade — ACE Inhibitors and ARBs

Renin-angiotensin-aldosterone system (RAAS) blockade with angiotensin-converting enzyme (ACE) inhibitors (e.g., enalapril, lisinopril, ramipril) or angiotensin receptor blockers (ARBs) (e.g., losartan, valsartan, irbesartan) reduces intraglomerular pressure and proteinuria independently of their blood pressure-lowering effect. These are first-line agents for all patients with diabetic nephropathy who have UACR > 30 mg/g and hypertension. The target blood pressure is < 130/80 mmHg. Combining an ACE inhibitor with an ARB is not recommended due to increased risk of adverse events.

3. SGLT2 Inhibitors — The Nephroprotective Revolution

Sodium-glucose cotransporter-2 (SGLT2) inhibitors — empagliflozin (Jardiance), dapagliflozin (Farxiga), and canagliflozin (Invokana) — were initially developed as glucose-lowering agents but have proven to have remarkable, glucose-independent kidney-protective effects. The CREDENCE trial (canagliflozin) showed a 34% relative risk reduction in ESRD, and the DAPA-CKD trial (dapagliflozin) demonstrated benefit even in patients who did not have diabetes. SGLT2 inhibitors work by reducing hyperfiltration in the glomerulus (through tubuloglomerular feedback), decreasing intraglomerular pressure by the same mechanism that made high glucose harmful. They are now recommended in all patients with diabetic nephropathy and eGFR ≥ 20 mL/min who tolerate them.

4. GLP-1 Receptor Agonists

Glucagon-like peptide-1 (GLP-1) receptor agonists — semaglutide (Ozempic, Wegovy), liraglutide (Victoza), dulaglutide (Trulicity) — provide cardiovascular protection and emerging evidence of kidney protection. The FLOW trial (semaglutide) published in 2024 demonstrated a 24% reduction in kidney disease progression, making GLP-1 agonists an important component of the modern nephroprotective toolkit.

5. Finerenone — The Newest Tool

Finerenone (Kerendia) is a non-steroidal mineralocorticoid receptor antagonist (MRA) approved by the FDA and available in Mexico that reduces inflammation and fibrosis in the kidney through a mechanism distinct from ACE inhibitors and SGLT2 inhibitors. The FIDELIO-DKD trial showed a 18% reduction in ESRD or kidney function deterioration in patients with diabetic nephropathy already on maximum RAAS blockade. Finerenone represents an important addition for patients with persistent proteinuria despite other treatments.

6. Blood Pressure Management Beyond RAAS

Target blood pressure of < 130/80 mmHg requires combination therapy in most patients with advanced diabetic nephropathy. Calcium channel blockers (amlodipine) and diuretics (chlorthalidone, furosemide in later stages) are commonly added.

7. Dietary Modification

Dietary intervention is an important non-pharmacological tool. The general recommendations include: - Protein restriction: 0.6 to 0.8 g/kg of body weight per day in stages 3–4, to reduce proteinuria and slow progression. - Sodium restriction: < 2,300 mg/day to enhance blood pressure control. - Potassium restriction: Required in Stage 4–5 to prevent dangerous hyperkalemia. - Phosphorus restriction: To prevent renal bone disease.

All patients with diabetic nephropathy benefit from consultation with a renal dietitian as part of a multidisciplinary care team.

When Is Kidney Transplantation the Right Answer?

Kidney transplantation is the best treatment for end-stage renal disease caused by diabetic nephropathy. Compared to chronic hemodialysis, kidney transplant recipients have, on average, twice the 5-year survival rate. The quality of life improvement is profound: patients are freed from 3–4 hours of dialysis three days a week and regain energy, dietary flexibility, and normal fluid balance.

When Should Transplant Evaluation Begin?

Dr. César Eduardo González Muñoz recommends initiating transplant evaluation when the eGFR falls to approximately 20 mL/min/1.73m². This allows time for:

• Comprehensive cardiovascular workup (essential in diabetic patients, who have high rates of asymptomatic coronary artery disease)
• Optimization of glycemic and blood pressure control before surgery
• Completion of the immunological workup (blood typing, HLA typing, panel reactive antibody screening)
• Identification of a potential living donor if applicable

Waiting until dialysis is already required delays transplantation unnecessarily and is associated with worse outcomes.

Living vs. Deceased Donor Transplantation

There are two main sources of donor kidneys. A living donor transplant — from a biologically compatible family member or altruistic donor — offers superior long-term graft survival and can be scheduled electively, avoiding the unpredictability of the waiting list. A deceased donor transplant comes from a brain-dead individual whose family has consented to donation; waiting times in Mexico vary by region.

In my practice, I evaluate both options carefully with every patient. Living donor surgery carries low risk for the donor and outstanding outcomes for the recipient: median graft survival exceeds 15 years with modern immunosuppression protocols.

Kidney-Pancreas Transplant: An Option for Type 1 Diabetics

For patients with type 1 diabetes and ESRD, simultaneous kidney-pancreas transplantation (SPK) offers the unique possibility of curing both organ failures at once. The transplanted pancreas produces insulin independently, normalizing glucose metabolism without the need for insulin injections. SPK is performed at select high-volume transplant centers and requires careful patient selection, but offers the best long-term outcomes for eligible type 1 diabetic patients.

Immunosuppression After Transplant

Following kidney transplantation, patients take immunosuppressant medications — most commonly tacrolimus, mycophenolate mofetil, and prednisone — for life to prevent rejection. In diabetic patients, some immunosuppressants (particularly tacrolimus and prednisone) can exacerbate glucose control, requiring careful coordination between the transplant surgeon and endocrinologist. Dr. González works closely with endocrinology colleagues to manage post-transplant diabetes protocol.

Diabetic Nephropathy and the Cross-Border Patient

Mexicali, Baja California occupies a unique geographic position: it sits directly across the border from Calexico, California, just a 5-minute drive from the Port of Entry. For US Hispanic patients living in the Imperial Valley, Coachella Valley, San Diego, Phoenix, or Yuma — many of whom have significant rates of type 2 diabetes and limited access to specialist care — Centro Médico González offers board-certified transplant surgical care with no need for air travel or extended travel time.

Dr. César Eduardo González Muñoz holds Cédula Profesional 8274619, is certified by the Consejo Mexicano de Cirugía General, and operates within a COFEPRIS-certified facility. All surgical and evaluative procedures meet international standards, and the clinic team includes bilingual (Spanish-English) coordination staff to support US patients throughout the evaluation and treatment process.

Frequently Asked Questions About Diabetic Nephropathy

Can diabetic nephropathy be reversed?

In its early stages (Stage 1 and Stage 2), diabetic nephropathy can be partially reversed with aggressive glucose control and RAAS blockade — particularly if microalbuminuria is the only abnormality. In Stage 3 and beyond, progression can be significantly slowed but structural kidney scarring cannot be fully undone. The goal shifts from reversal to preservation of remaining function and delay of ESRD.

How long does it take for diabetes to cause kidney failure?

The timeline varies considerably between patients. In type 1 diabetes, nephropathy classically develops 10–20 years after diagnosis, with ESRD another 10 years later in untreated patients. In type 2 diabetes, the timeline is less predictable because many patients have had hyperglycemia for years before their diagnosis. With optimal modern treatment (SGLT2 inhibitors, RAAS blockade, GLP-1 agonists), progression to ESRD can be delayed by a decade or more.

What is the difference between diabetic nephropathy and chronic kidney disease?

Diabetic nephropathy is a specific type of CKD caused by diabetes. Chronic kidney disease (CKD) is a broader category that includes any cause of long-term kidney damage — including hypertension, glomerulonephritis, polycystic kidney disease, and others. Diabetic nephropathy accounts for approximately 40% of all CKD globally, making it the most common single cause.

What does foamy urine mean in a diabetic patient?

Persistent foamy or frothy urine in a diabetic patient is a warning sign of proteinuria — protein leaking into the urine through damaged glomeruli. Occasional foam after vigorous urination is normal, but foam that lingers and does not clear should prompt urine testing with a UACR. It is typically the earliest symptom patients notice, and it corresponds to Stage 2 or Stage 3 diabetic nephropathy.

Which medications protect the kidneys in diabetic nephropathy?

The four classes with the strongest evidence for kidney protection are: (1) ACE inhibitors or ARBs for RAAS blockade and blood pressure control; (2) SGLT2 inhibitors (empagliflozin, dapagliflozin) which reduce intraglomerular pressure and are now standard of care; (3) GLP-1 receptor agonists (semaglutide, liraglutide) with cardiovascular and emerging renal benefits; and (4) finerenone, a non-steroidal MRA that reduces kidney inflammation and fibrosis.

At what eGFR should a diabetic patient be referred for kidney transplant?

Transplant evaluation should begin when the eGFR falls to approximately 20 mL/min/1.73m². This allows adequate time to complete the cardiovascular workup, immunological testing, and identification of a potential living donor before dialysis becomes necessary. Pre-emptive transplantation — performed before the patient ever starts dialysis — is associated with the best long-term outcomes and is our preferred approach whenever feasible.

Is kidney transplant safe for diabetic patients?

Yes. Diabetic kidney disease is the most common indication for kidney transplantation worldwide, and outcomes in diabetic recipients have improved dramatically over the last two decades with modern immunosuppression and cardiovascular management. The key to a successful outcome is thorough preoperative cardiac evaluation, since diabetic patients have higher rates of asymptomatic coronary disease, and close post-transplant glucose monitoring.

Can a patient on dialysis still get a kidney transplant?

Yes. Patients on dialysis remain eligible for transplantation, and transplantation still offers superior survival compared to remaining on chronic dialysis. However, pre-emptive transplantation (before dialysis starts) is associated with better outcomes, which is why early referral is so important.

How do I find out if I have diabetic nephropathy?

Ask your primary care physician or endocrinologist for two tests: a urine albumin-to-creatinine ratio (UACR) and a serum creatinine with calculated eGFR. These should be performed annually in every patient with diabetes. If either is abnormal, a referral to a nephrologist or transplant surgeon is appropriate to discuss next steps.

Taking the Next Step: Consultation with Dr. César González

Diabetic nephropathy is a serious but manageable condition. The trajectory of this disease is not fixed — the right interventions at the right time can preserve decades of kidney function and, when ESRD does arrive, kidney transplantation can restore a full, active life. The key is not to wait for symptoms to become severe.

If you or a family member has diabetes and has not had a recent kidney function evaluation, or if you have been told your kidneys are failing and want to understand your transplant options, I invite you to schedule a consultation at Centro Médico González in Mexicali. Our clinic is located at Blvd. Francisco L. Montejano 1188, Fracc. Fovissste, 21020 Mexicali, B.C. — five minutes from the Calexico border crossing — and can be reached at +52-686-338-3848. We see patients from across Baja California, the Imperial Valley, and throughout the US Southwest.

*Dr. César Eduardo González Muñoz is a board-certified transplant and hepatobiliary surgeon with 20 years of experience and more than 2,000 procedures. He holds Cédula Profesional 8274619 and operates within a COFEPRIS-certified surgical center (COFEPRIS 21020353A00412) in Mexicali, B.C., Mexico.*